Articles
Antimicrobial peptides – evolution’s answer to microbial resistance?

Antimicrobial peptides – evolution’s answer to microbial res...

As the increase in bacterial resistance to conventional antibiotics becomes an ever more prevalent problem, Jan Alenfall discusses a new class of drugs known as antimicrobial peptides (AMPs) and the potential they have for helping to manage resistant infections. Antimicrobial peptides (AMPs) are an ancient group of defence molecules. They display multiple modes of action, such as bactericidal, fungicidal and cytolytic properties, as well as having immunomodulating properties...

Articles
What will 2010 bring for pharma?

What will 2010 bring for pharma?

As the turn of the year fast approaches, Paul Tunnah wonders what growth the pharma industry can expect in 2010 and asks for pharmaphorum readers to present their views. There is no doubt it has been a challenging year for pharma so far as with many other industries. Further consolidation has been observed with big pharma whilst many biotech companies struggle for much-needed investment in these challenging times...

Articles
What Are IDEAs Made Of: The value proposition

What Are IDEAs Made Of: The value proposition

pharmaphorum is proud to introduce the first piece in a regular column every two weeks by experienced strategic consultant Mike Rea, who takes a fresh look at pharma marketing and challenges our current perceptions. At IDEA, we use Macs. They’re self-evidently better machines than PCs. It is rare to meet a client who wouldn't also prefer to use a Mac...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. AbbVie's Cerevel takeover delivers Parkinson's approval
  2. FDA clears first drug for MCT8 deficiency
  3. Novartis taps China's Abogen for autoimmunity TCE
  4. AZ takes stake in Summit Therapeutics in $2bn deal
  5. PhRMA hires ex-House Majority Leader Eric Cantor as its CEO

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more